Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
Iolanda Conde
IC
Fernandes
Marta
M
Gonçalves
Maria
M
dos Anjos Teixeira
Cristina
C
Gonçalves
Jorge
J
Coutinho
Manuela
M
Selores
Rosário
R
Alves
Margarida
M
Lima
D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D015703:Antigens, CD / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000074301:CD52 Antigen; D005434:Flow Cytometry; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000378:metabolism*; D012878:Skin Neoplasms / Q000188:drug therapy*
D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab